From gene to proteinâ€”experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension by Sheila K. Patel et al.
REVIEW ARTICLE
published: 24 June 2014
doi: 10.3389/fphys.2014.00227
From gene to protein—experimental and clinical studies of
ACE2 in blood pressure control and arterial hypertension
Sheila K. Patel1, Elena Velkoska1, Melanie Freeman1, Bryan Wai1,2, Terase F. Lancefield1 and
Louise M. Burrell1,2,3*
1 Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia
2 Department of Cardiology, Austin Health, University of Melbourne, Heidelberg, VIC, Australia
3 Department of Cardiology, The Northern Hospital, University of Melbourne, Epping, VIC, Australia
Edited by:
Marcelo Roberto Choi, National
Scientific and Technical Research
Council (CONICET), Argentina
Reviewed by:
Geoffrey A. Head, Baker IDI Heart
and Diabetes Institute, Australia
Belisario E. Fernandez, University of
Buenos Aires, Argentina
Mariela Gironacci, Universidad de
Buenos Aires, Argentina
*Correspondence:
Louise M. Burrell, Department of
Medicine, Austin Health, University
of Melbourne, Level 7, Lance
Townsend Building, 145 Studley
Road, Heidelberg, VIC 3084,
Australia
e-mail: l.burrell@unimelb.edu.au
Hypertension is a major risk factor for stroke, coronary events, heart and renal failure, and
the renin-angiotensin system (RAS) plays a major role in its pathogenesis. Within the RAS,
angiotensin converting enzyme (ACE) converts angiotensin (Ang) I into the vasoconstrictor
Ang II. An “alternate” arm of the RAS now exists in which ACE2 counterbalances
the effects of the classic RAS through degradation of Ang II, and generation of the
vasodilator Ang 1-7. ACE2 is highly expressed in the heart, blood vessels, and kidney.
The catalytically active ectodomain of ACE2 undergoes shedding, resulting in ACE2 in the
circulation. The ACE2 gene maps to a quantitative trait locus on the X chromosome in
three strains of genetically hypertensive rats, suggesting that ACE2 may be a candidate
gene for hypertension. It is hypothesized that disruption of tissue ACE/ACE2 balance
results in changes in blood pressure, with increased ACE2 expression protecting against
increased blood pressure, and ACE2 deficiency contributing to hypertension. Experimental
hypertension studies have measured ACE2 in either the heart or kidney and/or plasma, and
have reported that deletion or inhibition of ACE2 leads to hypertension, whilst enhancing
ACE2 protects against the development of hypertension, hence increasing ACE2 may
be a therapeutic option for the management of high blood pressure in man. There
have been relatively few studies of ACE2, either at the gene or the circulating level in
patients with hypertension. Plasma ACE2 activity is low in healthy subjects, but elevated
in patients with cardiovascular risk factors or cardiovascular disease. Genetic studies have
investigated ACE2 gene polymorphisms with either hypertension or blood pressure, and
have produced largely inconsistent findings. This review discusses the evidence regarding
ACE2 in experimental hypertension models and the association between circulating ACE2
activity and ACE2 polymorphisms with blood pressure and arterial hypertension in man.
Keywords: renin angiotensin system, angiotensin converting enzyme, angiotensin converting enzyme 2, blood
pressure, hypertension
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death and
disability worldwide (World Health Organization, 2011), and
hypertension is the most common risk factor for CVD (Kearney
et al., 2005). The renin angiotensin system (RAS) plays a major
role in the pathogenesis of hypertension, which is a risk fac-
tor for coronary events, stroke, kidney failure, and heart fail-
ure (Johnston, 1994; Dzau, 2005). Within the RAS, angiotensin
converting enzyme (ACE) converts angiotensin (Ang) I into
Abbreviations: ACE, angiotensin converting enzyme; ACE2, angiotensin convert-
ing enzyme 2; ADAM17, a disintegrin and metalloproteinase; Ang, angiotensin;
AT1R, angiotensin type 1 receptor; AT2R, angiotensin type 2 receptor; atRA,
all-trans retinoic acid; CV, cardiovascular; CVD, cardiovascular disease; DOCA,
deoxycorticosterone; KO, knockout; PVN, periventricular nucleus; RAS, renin
angiotensin system; rhACE2, recombinant human ACE2; RVLM, rostral ventrolat-
eral medulla; SD, Sprague Dawley; SHR, spontaneously hypertensive rat; SNP, sin-
gle nucleotide polymorphism; STNx, subtotal nephrectomy; WKY, Wistar-Kyoto;
XNT, xanthenone.
the vasoconstrictor Ang II, which mediates its effects via the
angiotensin type 1 receptor (AT1R). Ang II has actions to raise
blood pressure through vasoconstriction and salt and water
retention (Figure 1). In experimental models, stimulation of
angiotensin II type 2 receptor (AT2R) may counteract AT1R
mediated effects either directly or by modulating AT1R signaling
(Lemarie and Schiffrin, 2010;McCarthy et al., 2013) Inman, ther-
apeutic strategies that block RAS activation using ACE inhibitors
or Ang II receptor blockers are first line therapy in hypertension
and have beneficial effects on morbidity and mortality.
The discovery of angiotensin converting enzyme 2 (ACE2)
(Donoghue et al., 2000; Tipnis et al., 2000) more than a decade
ago has led to the concept of an “alternate” arm of the RAS. ACE2
has now been identified in many tissues including blood vessels
(Zulli et al., 2006, 2008; Sluimer et al., 2008), heart (Donoghue
et al., 2000; Burrell et al., 2005; Ohtsuki et al., 2010), kidney
(Tikellis et al., 2003; Mizuiri et al., 2008; Reich et al., 2008),
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FIGURE 1 | Opposing arms of the renin angiotensin system. Angiotensin
converting enzyme (ACE) converts angiotensin (Ang) I to Ang II, which exerts
its deleterious effects via the angiotensin type 1 receptor (AT1R). Ang II can
also act on the angiotensin type 2 receptor (AT2R) which can counteract
AT1R mediated effects. In the opposing arm, ACE2 degrades Ang II to Ang
1-7, which is thought to exert beneficial effect via the mas receptor.
liver (Paizis et al., 2005), and brain (Doobay et al., 2007). The
ACE2 amino acid sequence shares approximately 40% homology
with the N-terminal catalytic domain of ACE, and a hydropho-
bic region near the C-terminus likely to serve as a membrane
anchor. Like ACE, ACE2 is a type 1 membrane protein with the
catalytic domain on the extracellular surface (Donoghue et al.,
2000; Tipnis et al., 2000) and the ACE2 protein is encoded by the
ACE2 gene located on chromosome Xp22.
ACE2 is a monocarboxypeptidase, and in vitro can catalyze
cleavage of the C-terminal residue of the peptides Ang I, des-
Arg-bradykinin, neurotensin 1–13, and kinetensin (Donoghue
et al., 2000), as well as catalyzing the hydrolysis of the C-terminal
residue of Ang II (Tipnis et al., 2000). ACE2 can hydrolyze apelin-
13 and dynorphin A 1–13 with high activity (Vickers et al.,
2002), but its most important biological effect is to degrade
Ang II to Ang 1-7, which it does with a catalytic efficiency that
is 400-fold higher with Ang II as a substrate than with Ang
I (Figure 1). Thus, ACE2 may limit the vasoconstrictor action
of Ang II through its degradation, as well as counteracting the
actions of Ang II through the formation of Ang 1-7 which is
reported to have vasodilatory and anti-fibrotic actions (Tallant
and Clark, 2003) at the Ang 1-7 or mas receptor (Santos et al.,
2003). Ang 1-7 has other actions of cardiovascular relevance
including natriuresis, diuresis, inhibition of cell growth and anti-
atherosclerotic effects; the reader is referred to a recent review
for a detailed description of the actions of Ang 1-7 (Santos,
2014).
This review will discuss the evidence regarding ACE2 in exper-
imental models of primary and secondary arterial hypertension,
the association between circulating ACE2 activity and blood
pressure and hypertension in man, as well as genetic association
studies that have investigated ACE2 polymorphisms with blood
pressure and/or arterial hypertension.
EXPERIMENTAL STUDIES OF ACE2
It is hypothesized that disruption of tissue ACE/ACE2 balance
may result in changes in blood pressure, with increased ACE2
expression protecting against increased blood pressure, and ACE2
deficiency leading to increased blood pressure (Yagil and Yagil,
2003). Table 1 summarizes the experimental studies that have
measured ACE2 gene, protein and/or activity, in either the heart,
kidney and/or plasma, usually at one time point, and generally in
Frontiers in Physiology | Clinical and Translational Physiology June 2014 | Volume 5 | Article 227 | 2
Patel et al. Hypertension and ACE2
Table 1 | ACE2 and experimental hypertension.
Aetiology Model/Strain of
hypertension
Control ACE2 in hypertensive vs. control group References
PRIMARY HYPERTENSION
Genetic SHR WKY ↓ Cardiac ACE2 mRNA, protein and activity Zhong et al., 2004; Diez-Freire
et al., 2006; Ferreira et al., 2011;
Tan et al., 2011; Yang et al., 2013
↓ Kidney ACE2 mRNA, protein and activity Crackower et al., 2002; Zhong
et al., 2004; Tikellis et al., 2006;
Tan et al., 2011
↓ ACE2 protein in rostral ventrolateral medulla Yamazato et al., 2007
SHR + 8% salt diet SHR + 1% salt diet ↓ LV ACE2 mRNA and protein Varagic et al., 2010
↔ LV ACE2 mRNA and activity Varagic et al., 2012
Stroke-prone SHR WKY ↓ Kidney ACE2 mRNA and protein Crackower et al., 2002
↔ kidney (cortical and medullary) ACE2
mRNA, and activity
Kamilic et al., 2010
Sabra salt-sensitive rat
(SBH/y) + normal chow
Sabra salt-resistant (SBN/y)
+ normal chow
↓ Kidney ACE2 mRNA and protein Crackower et al., 2002
SBH/y + DOCA-salt SBN/y + DOCA-salt ↓ Kidney ACE2 mRNA and protein Crackower et al., 2002
SBH/y + 8% salt diet SBH/y + normal chow ↔ Cardiac ACE2 protein Landau et al., 2008
Dahl salt-sensitive Dahl salt-resistant ↓ Cardiac ACE2 mRNA and protein Takeda et al., 2007
Transgenic models
TGR(mREN2)27 SD ↔ Kidney (cortical and medullar) ACE2 mRNA,
and kidney ACE2 activity
Kamilic et al., 2010
mREN(2). Lewis Lewis rats ↔ Cardiac ACE2 activity, ↓ kidney cortical
ACE2 activity
Pendergrass et al., 2008
TG(hRen + hAGT) Non-TG mice ↔ Kidney ACE2 activity, ↑ brain ACE2 activity Xia et al., 2009
SECONDARY HYPERTENSION
Endocrine DOCA + 1% salt in water + Uninephrectomised rat ↔ Plasma ACE2 activity Ocaranza et al., 2011
uninephrectomy in SD (No DOCA + water) ↔ LV ACE2 mRNA Santiago et al., 2010
DOCA + 1% salt in water + Uninephrectomised mice ↓ ACE2 protein and activity in hypothalamus Xia et al., 2013
uninephrectomy in mice (no DOCA + water) ↑ ACE2 activity in cerebrospinal fluid
Ang II infusion in SD rat Vehicle infusion ↑ Cardiac ACE2 mRNA and protein, ↔ kidney
ACE2 mRNA and protein
Meng et al., 2014
↓ Kidney (cortical and medullary) ACE2 protein Prieto et al., 2011
↓ ACE2 mRNA and protein in paraventricular
nucleus
Sriramula et al., 2011
Ang II infusion in C57BL/6
mice
Vehicle infusion ↑ Plasma ACE2 activity, ↑ cardiac ACE2
mRNA, ↓cardiac ACE2 protein and activity
Patel et al., 2013a
↓ Kidney ACE2 protein Zhong et al., 2011
Renal Goldblatt hypertension in SD Sham operation ↓ Kidney ACE2 mRNA and protein Prieto et al., 2011; Bai et al., 2013
Goldblatt hypertension in
HanSD
Sham operation ↑ Kidney ACE2 activity Burgelova et al., 2009
Subtotal nephrectomy Sham operation ↑ Plasma ACE2 activity Burchill et al., 2008
(Acute kidney failure) in SD ↑ LV ACE2 mRNA, protein and activity Burchill et al., 2008; Velkoska
et al., 2011
↓ Kidney cortical ACE2 mRNA, ↓ kidney
(cortical and medullary) ACE2 activity
Velkoska et al., 2010
Subtotal nephrectomy
(chronic kidney failure) in SD
Sham operation ↔ Plasma ACE2 activity, ↔ LV ACE2 mRNA
and protein
Burrell et al., 2012
↓ Kidney (cortical and medullary) ACE2 mRNA
and activity
Dilauro et al., 2010; Burrell et al.,
2012
↑ Increased ACE2; ↓ decreased ACE2; ↔ no change in ACE2. Agt, angiotensinogen; Ang II, angiotensin II; DOCA, deoxycorticosterone; HanSD, Hannover-Spague
Dawley rat; h, human; LV, left ventricle; Ren, renin; SBH, Saber Salt sensitive rat; SBN, Saber Salt resistant rat; SD, Sprague Dawley rat; SHR, spontaneously
hypertensive rat; TG, transgenic; TGR(mREN2)27, transgenic renin hypertensive model; WKY, Wistar Kyoto rat.
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animals with established hypertension, and compared results to a
“normotensive” control.
ACE2 AND PRIMARY HYPERTENSION
There are several lines of evidence that support a role for ACE2 in
the development of primary experimental hypertension. Firstly,
the gene for ACE2 maps to a defined quantitative trait locus on
the X chromosome, previously identified as a quantitative locus
for blood pressure (Crackower et al., 2002), in three strains of
genetically hypertensive rats the Sabra salt-sensitive rat, sponta-
neously hypertensive rat (SHR) and the stroke-prone SHR. ACE2
may play a role in the pathogenesis of genetic hypertension. In
a study that examined ACE2 expression in the kidneys of SHR
and normotensive Wistar-Kyoto (WKY) rats at birth, 6 weeks
and adulthood (Tikellis et al., 2006), kidney ACE2 expression
fell with the onset of hypertension in SHR compared to WKY,
and remained reduced in the adult SHR kidney (Tikellis et al.,
2006). Similarly, although cardiac ACE2 activity was not signif-
icantly different between 10 days old SHR and WKY rats, by 3
months cardiac ACE2 activity was reduced in SHR compared to
age-matched WKY rats (Diez-Freire et al., 2006).
In adult rats with established hypertension, there was an asso-
ciation between reduced kidney ACE2 and blood pressure in SHR
and in stroke-prone SHR, compared to levels in normotensive
rats (Crackower et al., 2002). Reduced cardiac ACE2 expres-
sion (Zhong et al., 2004; Ferreira et al., 2011; Tan et al., 2011;
Yang et al., 2013) and activity (Diez-Freire et al., 2006) has been
reported in SHR compared toWKY rats, in Dahl salt-sensitive rats
compared to salt-resistant rats (Takeda et al., 2007), and in salt-
loaded SHR compared to SHR fed a low salt diet (Varagic et al.,
2010). A subsequent study showed no change in cardiac ACE2
gene and activity in salt-loaded SHR (Varagic et al., 2012), and
similarly in Sabra salt-sensitive rats, salt loading did not change
cardiac ACE2 protein compared to salt-resistant Sabra rats on a
normal diet (Landau et al., 2008).
The results with regard to regulation of tissue ACE2 in trans-
genic models of hypertension are mixed. Transgenic overexpres-
sion of renin in Sprague Dawley (SD) rats did not change kidney
ACE2 expression and activity (Kamilic et al., 2010), but in trans-
genic Lewis rats, kidney cortical ACE2 was reduced with no
change in cardiac ACE2 (Pendergrass et al., 2008). Similarly, in
transgenic mice overexpressing human renin and angiotensino-
gen, no change in ACE2 activity was observed in the kidney,
however this study reported elevated ACE2 activity in the brain
of transgenic mice compared to non-transgenic mice (Xia et al.,
2009). The disparity in observed changes highlights the impor-
tance of the strain and model used when examining the role of
ACE2 in hypertension.
ACE2 AND SECONDARY HYPERTENSION
Although a potentially reversible cause of hypertension can be
identified in less than 10% of patients with hypertension, the
overall high prevalence of hypertension means that secondary
forms can affect millions of patients worldwide. Dysregulation
of ACE2 has been reported in experimental models of sec-
ondary hypertension, such as endocrine hypertension [deoxy-
corticosterone (DOCA)-salt, Ang II infusion], renal failure
(subtotal nephrectomy), and renal artery stenosis (Goldblatt
hypertension).
In DOCA-salt hypertension in the rat, plasma ACE2 activity
(Ocaranza et al., 2011) and left ventricular ACE2 gene expression
(Santiago et al., 2010) were unchanged compared to uninephrec-
tomised rats with no DOCA or high salt intake. Hypertension
secondary to short term Ang II infusion (2 weeks) in SD rats
resulted in decreased kidney cortical andmedullary ACE2 protein
(Prieto et al., 2011), although chronic Ang II infusion (4 weeks) in
SD rats increased cardiac ACE2 expression with no change in kid-
ney ACE2 (Meng et al., 2014). In mice, a 2 week Ang II infusion
increased plasma ACE2 activity and cardiac ACE2 gene expres-
sion (Patel et al., 2013a), but reduced cardiac ACE2 protein and
activity (Patel et al., 2013a) and kidney protein (Zhong et al.,
2011).
In the Goldblatt (2-kidney, 1-clip) hypertensive SD rat model
with kidney impairment, kidney ACE2 gene and protein expres-
sion were reduced in both clipped and non-clipped kidneys
(Prieto et al., 2011; Bai et al., 2013), while renal ACE was sig-
nificantly elevated, resulting in increased Ang II and reduced
Ang 1-7 levels (Prieto et al., 2011). However, others have shown
that kidney ACE2 and Ang 1-7 levels are increased in Goldblatt
hypertension in Hannover SD rats without kidney impairment
(Burgelova et al., 2009). In a short-term kidney failure model
of hypertension induced by subtotal nephrectomy (STNx), we
reported organ specific regulation of ACE2 with increased plasma
and cardiac ACE2 (Burchill et al., 2008; Velkoska et al., 2011),
and decreased kidney ACE2 (Velkoska et al., 2010). These data
suggest that during the early stages of kidney impairment, acti-
vation of cardiac ACE2 may protect the heart against the adverse
effects of an activated RAS, whilst depletion of kidney ACE2 con-
tributes to kidney injury. Furthermore, in a long-term model of
chronic kidney failure induced hypertension, we reported a per-
sistent reduction in renal ACE2, but the early elevation in cardiac
ACE2 was no longer evident, suggesting that this may contribute
to ongoing cardiac dysfunction with renal disease progression
(Burrell et al., 2012). In both short-term and chronic models of
kidney failure induced hypertension, reduced kidney ACE2 was
associated with increased blood pressure (Dilauro et al., 2010;
Velkoska et al., 2010; Burrell et al., 2012).
ACE2 AND CENTRAL CONTROL OF BLOOD PRESSURE
ACE2 has also been identified in regions of the mouse brain
involved in control of cardiovascular function (Doobay et al.,
2007), with ACE2 gene deletion resulting in impaired barore-
flex sensitivity and autonomic function (Xu et al., 2011), thus
supporting a potential role of ACE2 in central blood pressure
regulation. ACE2 protein expression was reduced in the rostral
ventrolateral medulla (RVLM) of SHR compared to WKY rats,
and overexpression of ACE2 in the RVLM decreased blood pres-
sure in SHR but not WKY rats (Yamazato et al., 2007). Similarly
reduced ACE2 activity in the brain stem was observed in genet-
ically hypertensive mice (Xia et al., 2009), while specific ACE2
overexpression in the brain restored baroreflex function and con-
tributed to the reduction of blood pressure in these mice (Xia
et al., 2009). In Ang II induced hypertension, reduced ACE2 gene
and protein expression in the periventricular nucleus (PVN) was
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reported, and adenoviral injection directly in the PVN reduced
blood pressure (Sriramula et al., 2011). A recent study in DOCA-
salt hypertensivemice, demonstrated that low-renin hypertension
was associated with reduced ACE2 expression and activity in the
hypothalamus and increased ACE2 activity in the cerebrospinal
fluid, as a result of increased shedding of ACE2 from the tis-
sue membrane by ADAM17 (a disintegrin andmetalloproteinase)
(Xia et al., 2013). Furthermore, knockdown of ADAM17 pre-
vented the reduction of ACE2 in the brain, which was associated
with a blunting of DOCA-salt hypertension (Xia et al., 2013). This
data suggests that central ACE2 shedding by ADAM17 can also
contribute to the development of hypertension.
EFFECTS OF ACE2 INHIBITION/DELETION AND
OVEREXPRESSION ON BLOOD PRESSURE
The development of ACE2 inhibitors (Dales et al., 2002) and
approaches to enhance ACE2 including viral transfection, recom-
binant ACE2 and ACE2 activators (Hernandez Prada et al., 2008;
Kulemina and Ostrov, 2011), have helped to clarify whether ACE2
deficiency has a pathophysiological role in the onset of hyper-
tension or is simply a consequence of elevated blood pressure.
Treatment with the ACE2 inhibitor MLN-4760 had no effect
on blood pressure in hypertensive mRen2 transgenic rats (Trask
et al., 2010), nor in wild type mice (Tikellis et al., 2008). In
mice with genetic deletion of ACE2 on the C57BL/6 background,
ACE2 deficiency was associated with only a modest increase in
blood pressure (Gurley et al., 2006; Tikellis et al., 2012), but
enhanced susceptibility to Ang II-induced hypertension (Gurley
et al., 2006). Other studies have shown no change in blood pres-
sure in ACE2 knock-out (KO)mice compared to control C57BL/6
(Tikellis et al., 2008; Shiota et al., 2010), but once diabetes was
induced in ACE2 KO mice, hypertension did develop (Tikellis
et al., 2008). This suggests that ACE2 plays a compensatory role
in the setting of disease, but not in normal physiology. This
notion is supported by results from ACE2 overexpression studies.
For example, cardiac ACE2 gene transfer reduced blood pres-
sure and attenuated cardiac hypertrophy and fibrosis in SHR,
but had no effect in normotensive WKY rats (Diez-Freire et al.,
2006), and intra-cardiac ACE2 overexpression protected from
angiotensin II-induced cardiac hypertrophy and fibrosis, but had
no effect in vehicle infused rats (Huentelman et al., 2005). In addi-
tion, transgenic ACE2 overexpression in vessels of stroke-prone
SHR reduced blood pressure and improved endothelial function
(Rentzsch et al., 2008).
EFFECTS OF ENHANCING ACE2 ACTIVITY IN EXPERIMENTAL
MODELS OF HYPERTENSION
It has been suggested that enhancing ACE2 activity may be a
useful therapeutic approach in the management of high blood
pressure. Current approaches to increase ACE2 activity include
compounds that can activate ACE2 such as xanthenone (XNT)
(Hernandez Prada et al., 2008) and all-trans retinoic acid (atRA)
(Zhong et al., 2004). The compound atRA increased cardiac and
kidney levels of ACE2 in SHR, reduced blood pressure and attenu-
atedmyocardial damage (Zhong et al., 2004). In vitro studies show
that the ACE2 activator, XNT shifts the conformational equilib-
rium of ACE2 to increase its activity (Hernandez Prada et al.,
2008), and acute administration in SHR reduced blood pres-
sure, while chronic infusion reversed cardiac and renal fibrosis
(Hernandez Prada et al., 2008). XNT infusion increased cardiac
gene and protein ACE2 levels in SHR, which was associated with
increased Ang 1-7 production and inhibition of ERK signaling
(Ferreira et al., 2011). Central administration of XNT reduced
acute air jet stress-induced increases in blood pressure (Martins
Lima et al., 2013). By contrast, a recent study reported that XNT
mediates its effects without activation of ACE2 (Haber et al.,
2014). In a model of Ang II–induced acute hypertension, reduc-
tion in blood pressure was markedly enhanced by XNT with no
effect on plasma nor kidney ACE2 activity (Haber et al., 2014).
As the blood pressure-lowering effects of XNT were seen in both
wild-type and ACE2 KO mice, this study concludes that the
effects of XNT cannot be due to the activation of ACE2 (Haber
et al., 2014). Further studies are needed to determine the pre-
cise mechanism of the antihypertensive and antifibrotic benefits
of XNT.
A more direct approach to increase ACE2 is through recom-
binant ACE2. Recombinant human ACE2 (rhACE2) treatment
partially reduced the pressor effect of an Ang II infusion with-
out affecting basal systolic blood pressure in vehicle-treated mice
(Zhong et al., 2010). Administration of rhACE2 also improved
Ang II induced cardiac remodeling and dysfunction with attenu-
ation of signaling pathways relevant for hypertrophy and fibrosis
(Zhong et al., 2010). Both rhACE2 (Wysocki et al., 2010) and
mouse recombinant ACE2 (Ye et al., 2012) attenuated Ang II
induced hypertension in mice, with no effect on blood pres-
sure in normotensive mice (Wysocki et al., 2010). However the
initial increase in serum ACE2 observed in mice infused with
rhACE2 was not sustained long-term due to the development
of antibodies (Wysocki et al., 2010). The Ang II induced pres-
sor effect in WKY rats was blunted with co-administration of
rhACE2 (Lo et al., 2013), while in SHR 2-weeks of rhACE2 par-
tially attenuated the blood pressure in association with reduced
plasma Ang II levels and increased Ang 1-7 (Lo et al., 2013).
Furthermore, lowering plasma and renal cortex levels of Ang II
with rhACE2 over 4 weeks was associated with reduced blood
pressure and slower progression of diabetic nephropathy in dia-
betic Akita mice (Oudit et al., 2010). A recent study examined
the effect of intravenous administration of rhACE2 in healthy
human subjects and found that a single rhACE2 dose of 100–
1200µg/kg was well tolerated and resulted in a dose-dependent
increase in plasma ACE2, with no change in blood pressure or
heart rate (Haschke et al., 2013). No antibodies to rhACE2 were
detected 7, 14, and 28 days after the last dose of rhACE2 (Haschke
et al., 2013). Studies evaluating the efficacy of this approach
to lower blood pressure are currently lacking in patients with
hypertension.
CLINICAL STUDIES OF CIRCULATING ACE2 AND
HYPERTENSION
ACE2 undergoes “shedding” from endothelial cells to release
the catalytically active ectodomain into the circulation (Lambert
et al., 2005; Patel et al., 2013b). This process involves the pro-
teinase ADAM17 (Lambert et al., 2005, 2008), and results in
soluble ACE2, that can be measured in human plasma (Rice et al.,
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2006; Lew et al., 2008; Freeman et al., 2011; Chong et al., 2012;
Soro-Paavonen et al., 2012; Ortiz-Perez et al., 2013; Roberts et al.,
2013; Uri et al., 2014) using an ACE2-specific quenched fluores-
cent substrate assay described by Vickers et al. (2002). There are
few studies that have specifically investigated whether circulating
ACE2 activity is a biomarker of CVD in man, or if it is associated
with blood pressure or hypertension. The results from the avail-
able studies suggest that plasma ACE2 activity is low in normal
healthy volunteers (Lew et al., 2008), but increased in patients
with cardiovascular risk factors or CVD (Freeman et al., 2011;
Chong et al., 2012).
The Leeds Family study measured plasma ACE2 activity levels
in healthy subjects and family members (Rice et al., 2006). Plasma
ACE2 activity was detectable in only 40/537 subjects, and these
subjects had significantly higher systolic and diastolic blood pres-
sure compared to those without detectable plasma ACE2 (Rice
et al., 2006). This study also provided evidence of genetic influ-
ences on circulating ACE2 activity and estimated that up to 67%
of the variability in circulating ACE2 levels was explained by
hereditable factors (Rice et al., 2006). This conclusion was based
on the observation that among the 40 subjects with detectable
ACE2 activity, half had at least one other family member with
detectable ACE2 activity (Rice et al., 2006).
A number of other studies suggest an association between
ACE2 activity and blood pressure. In patients with type 1 diabetes
(n = 859), serum ACE2 activity was significantly higher in male
compared to female patients, and was positively correlated with
systolic blood pressure in bothmales and females (Soro-Paavonen
et al., 2012). In patients with chronic kidney disease (n = 59),
hemodialysis patients (n = 100) and kidney transplant recipients
(n = 80) (Roberts et al., 2013), male patients had significantly
higher plasma ACE2 activity compared to female patients; in
females, plasma ACE2 activity was significantly associated with
post-hemodialysis systolic blood pressure with a 4% increase in
ACE2 for every 1mmHg increase in systolic blood pressure. A
recent study (Uri et al., 2014) has also reported that serum ACE2
activity was higher in hypertensive patients (n = 239) compared
to healthy individuals (n = 45).
Others have reported no association between circulating
ACE2 activity and hypertension. For example, monocyte-derived
macrophage ACE2 activity in untreated hypertensive patients was
not different to levels in normotensive individuals (Keidar et al.,
2007), and in patients with ST-elevation myocardial infarction
(n = 95), there was no association between ACE2 activity and
hypertension (Ortiz-Perez et al., 2013). Whilst the studies by
Soro-Paavonen et al. (2012) and Roberts et al. (2013) show that
plasma ACE2 activity varies according to gender, most published
ACE2 activity studies have not taken gender into account in their
analysis.
ACE2 GENE ASSOCIATION STUDIES AND HYPERTENSION
There have been 17 studies since 2004 (summarized in Table 2)
investigating ACE2 single nucleotide polymorphisms (SNPs) with
blood pressure and/or hypertension (Burrell et al., 2013). These
studies have been mainly conducted in Chinese populations
(Huang et al., 2006; Yi et al., 2006; Zhong et al., 2006; Fan et al.,
2007, 2009; Niu et al., 2007; Zhao et al., 2010a,b) with only four
in Caucasians (Benjafield et al., 2004; Lieb et al., 2006; Patel et al.,
2012; Malard et al., 2013), one in Koreans (Song et al., 2011) and
one in an Indian population (Patnaik et al., 2014). Two ACE2
SNPs, rs2285666 and rs1978124 are among those most frequently
investigated in association studies. In three Chinese studies, sig-
nificant associations in women with the rs2285666 SNP with
either hypertension or systolic or diastolic blood pressure were
reported (Yi et al., 2006; Zhong et al., 2006; Niu et al., 2007). In
two of these studies, higher blood pressure was associated with
the A allele (Yi et al., 2006; Niu et al., 2007) but in the third study
it was the G allele (Zhong et al., 2006). Another study investi-
gated orthostatic blood pressure responses in 3630 Chinese Han
subjects and found no association with the rs2285666 SNP (Fan
et al., 2009).
Two meta-analyses of the rs2285666 SNP have been reported
with conflicting results (Zhou and Yang, 2009; Lu et al., 2012).
One study had a combined total of 2528 Chinese Han sub-
jects with hypertension and 2024 ethnicity matched normoten-
sive controls and reported no association with hypertension
(Zhou and Yang, 2009). The other study, a meta-analysis of
7251 hypertensive patients, reported a significant association
between the rs2285666 AA genotype with hypertension in females
only (Lu et al., 2012). However, this meta-analysis included
mixed ethnicities (Chinese Han, Chinese Dongxiang, Anglo-
Celtic) and reported significant heterogeneity in males, sug-
gesting that the A allele was associated with hypertension in
the Chinese Han subjects only. In one Korean study, the ACE2
SNPs rs1514282 and rs1514283 were found to be significantly
associated with diastolic pressure but not with hypertension
(Song et al., 2011). A recent study investigated the ACE2 gene
in 246 hypertensive subjects from Odisha, India, and reported
that the SNP rs2106809 TT genotype in females and the T
allele in males was associated with hypertension compared to
normotensive controls (Patnaik et al., 2014). Further studies
with ACE2 SNPs in other Indian populations will need to be
conducted.
The evidence of ACE2 gene associations in Caucasians is
also inconsistent. In a small case-control study conducted in
Anglo-Celtic Australian subjects with hypertension (n = 152) or
normotension (n = 193), four ACE2 SNPs were not associated
with hypertension (Benjafield et al., 2004). In another study of
healthy subjects participating in theMONICA Augsburg echocar-
diographic substudy, four ACE2 SNPs (rs4646156, rs879922,
rs4240157, and rs233575) were investigated but none were asso-
ciated with systolic blood pressure variation (Lieb et al., 2006).
However, in our own study of 503 Australian Caucasians with
type 2 diabetes (Patel et al., 2012), the prevalence of hypertension
was significantly higher in both men and women and was asso-
ciated with the G allele of the ACE2 SNP rs4240157 (Patel et al.,
2012).
In another analysis, three ACE2 SNPs (rs1514283, rs4646176,
and rs879922) were reported to be significantly associated with
the diastolic blood pressure response to a cold pressor test
in female Chinese subjects participating in the GenSalt study
(Huang et al., 2012). One study in the Chinese population
reported no association of ACE2 SNPs rs2106809 and rs2285666
with orthostatic blood pressure dysregulation in 3630 untreated
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Table 2 | ACE2 gene associations with blood pressure and/or hypertension.
References ACE2
variant
Population Gender Study design Sample size
(case:control)
Phenotype Significant
findings with
blood pressure
and/or
hypertension
Benjafield et al.,
2004
rs1978124
rs2285666
rs879922
rs714205
Australian white
Anglo-Celtic origin
Both Case-control 152:193 Hypertension No
Lieb et al., 2006 rs2285666
rs4646156
rs879922
rs4240157
rs233575
German Caucasian Both Cross-sectional 1674 Blood pressure in
Healthy subjects in the
MONICA Augsburg
echocardiographic
substudy
No
Huang et al.,
2006
rs1978124
rs2285666
Chinese population
of Han ethnicity
Both Case-control 494:484 Hypertension No
Yi et al., 2006 rs2285666 Chinese populations
of (a) Han ethnicity
(b) Dongxiang
ethnicity
Both Case-control (a) 198:131
(b) 120:102
Hypertension Yes
Zhong et al.,
2006
rs2285666 Chinese population
of Han ethnicity
Both Cross-sectional 353 Subjects with
metabolic syndrome
Yes
Niu et al., 2007 rs1978124
rs2285666
Chinese population
of Han ethnicity
Both Case-control 808:686 Hypertension Yes
Fan et al., 2007 rs2106809
rs2285666
rs4646155
rs879922
Chinese population
of Han ethnicity
Both Two studies
(a) Case-control (b)
Clinical trial
randomized to 4
treatment groups
(a) 973:969
(b) 3408
Hypertension Yes
Zhou and Yang,
2009
rs2285666 Chinese population
of Han ethnicity
Both Meta-analysis
(5 case-control
studies)
2528: 2024 Hypertension No
Fan et al., 2009 rs2106809
rs2285666
Chinese population
of Han ethnicity
Both Case-control 3630:826 Orthostatic blood
pressure in
Hypertensive patients
No
Zhao et al.,
2010a
rs4646174
rs879922
rs4646140
Chinese population
of Han ethnicity
Both Intervention study in
probands and their
families (parents,
siblings, spouses
and offspring)
participating in the
GenSalt Study
1906 Blood pressure
responses to dietary
potassium intake
Yes
Zhao et al.,
2010b
rs1514283
rs1514282
rs2074192
rs714205
rs4646176
rs2285666
Chinese population
of Han ethnicity
Both Intervention study in
probands and their
families (parents,
siblings, spouses
and offspring)
participating in the
GenSalt Study
1906 Blood pressure
responses to dietary
sodium intake
Yes
(Continued)
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Table 2 | Continued
References ACE2
variant
Population Gender Study design Sample size
(case:control)
Phenotype Significant
findings with
blood pressure
and/or
hypertension
Song et al., 2011 rs1514282
rs1514283
South Korean Both Cohort study 7551 Blood pressure Yes
Patel et al., 2012 rs1978124
rs2074192
rs4240157
rs4646156
rs4646188
Australian
Caucasians
Both Cohort study 503 Type 2 diabetes Yes
Lu et al., 2012 rs2285666 Mixed ethnicity of
Chinese Han,
Dongxiang, Li and
Australian Anglo
Celtic
Both Meta-analysis (9
case-control and 1
cross-sectional
study)
7251:3800 Hypertension Yes
Huang et al.,
2012
rs1514283
rs4646176
rs879922
Chinese population
of Han ethnicity
Both Probands and their
families (parents,
siblings, spouses
and offspring)
participating in the
GenSalt Study
1998 Blood pressure
response to cold
pressor test
Yes
Malard et al.,
2013
rs2074192
rs233575
rs2158083
rs1978124
Adolescents from 3
ethnicities, analysis
performed
separately:
French Canadian
European descent
Other (biological
parents of Asian,
Spanish, African
countries)
Both Cohort study 555 Blood pressure Yes
Patnaik et al.,
2014
rs2106809 South Asian
population from
Odisha, India
Both Case-control 246:274 Hypertension Yes
hypertensive patients compared to 826 normotensive subjects
(Fan et al., 2009).
The association of ACE2 SNPs with baseline blood pres-
sure and blood pressure changes over 5 years was examined
in 555 adolescents mainly of French Canadian or European
descent (Malard et al., 2013). This study restricted the analy-
ses to homozygous females. In European males the ACE2 SNP
rs2074192minor A allele was associated with a lower baseline
diastolic and systolic blood pressure after weight and height
adjustment. The ACE2 SNP rs233575 C allele was associated
with higher baseline systolic and diastolic blood pressure in
European males. In contrast, French Canadian females with
the rs233575 T allele had a 4mmHg higher baseline diastolic
blood pressure compared to the SNPs C allele. With regards
to ACE2 SNPs associated with changes in blood pressure from
the baseline visit, there were no significant associations with the
four ACE2 SNPs investigated in European or French Canadian
males. However in females of European descent, the rs2074192
A allele was associated with a change in systolic blood pressure
that was lower and the C allele of SNPs rs2333575 and rs2158083
were associated with a change in systolic blood pressure that
was higher compared to the alternative allele (Malard et al.,
2013). This study demonstrates that the association of the ACE2
SNPs with blood pressure was influenced by both gender and
ethnicity.
ACE2 GENE AND RESPONSES TO BLOOD PRESSURE
TREATMENT
A small number of dietary and pharmacological interventions
in Chinese populations have also been conducted in relation to
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ACE2 polymorphisms. The GenSalt study in Chinese Han sub-
jects examined responses to variation in sodium and potassium
intake (Zhao et al., 2010a). This study reported ACE2 SNPs to
be associated with the reduction in blood pressure in response to
potassium while on a high salt intake in males only (Zhao et al.,
2010a) and also with variations in sodium intake in males and
females combined (Zhao et al., 2010b). One study investigated the
blood pressure response to RAS blockade in Chinese Han sub-
jects (Fan et al., 2007), and reported that the diastolic pressure
response to ACE inhibition was 3.3mmHg greater in women with
the rs2106809 T allele after adjustments for age, pre-treatment
blood pressure, body mass index and fasting blood glucose. There
are no studies of ACE2 gene associations with blood pressure
treatment responses in Caucasian populations.
SUMMARY AND FUTURE DIRECTIONS
The experimental studies clearly support a physiological and
pathophysiological role for ACE2 in arterial hypertension, and
data is also available that increasing/activating ACE2 has benefi-
cial effects to lower blood pressure. As therapeutic strategies that
block the RAS using ACE inhibitors or Ang II receptor blockers
are first line therapy in hypertension, experimental studies are
needed that combine ACE2 activators/recombinant ACE2 with
RAS blockers to determine if this approach offers incremental
benefits.
There are very few clinical studies that have specifically inves-
tigated whether circulating ACE2 activity is associated with blood
pressure or hypertension. Plasma ACE2 activity levels are low in
healthy individuals, and may or may not be increased in patients
with hypertension. Males have higher circulating ACE2 activity
than females, but few reports have analyzed data according to
gender. There are 17 studies that have examined ACE2 genetic
associations with blood pressure and hypertension; the majority
are in Chinese populations, but the results have been inconsistent.
There are not yet any studies that combine genetic approaches
with measurement of plasma ACE2 activity. Large carefully con-
ducted clinical studies, designed with sufficient numbers and
power to allow separate analyses of males and females are urgently
needed in patients with hypertension to more precisely clar-
ify the potential role of ACE2 in blood pressure variation and
hypertension, and to uncover mechanisms that might offer novel
treatment targets.
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